The present invention relates to an improved pharmaceutical composition in the form of a coated oral tablet, with teneligliptin or the pharmaceutically acceptable salts thereof and metformin or the pharmaceutically acceptable salts thereof, for the treatment of type 2 diabetes mellitus. The pharmaceutical composition is obtained by means of wet granulation, using metformin ground to a fine powder and a low load of excipients consisting of a binder, in this case povidone, and magnesium stearate as a lubricant during compression. The use of ground metformin considerably improves the compressibility of same, allowing operative conditions to be optimised. Compared with the two active ingredients separately and vehiculised in the form of coated tablets, the improved pharmaceutical composition comprising the combination of teneligliptin and metformin show no differences in in vitro release (solution), and, moreover, improved the compressibility of the powder and the friability of the tablet s. The features mentioned distinguish this improved composition from other compositions containing the same active ingredients and using more excipients. Said composition is therefore the main subject matter of the present invention.La presente invención se refiere a una composición farmacéutica mejorada en la forma de comprimido oral recubierto, con Teneligliptina o sus sales farmacéuticamente aceptables y Metformina o sus sales farmacéuticamente aceptables para el tratamiento de diabetes mellitus tipo 2. Dicha composición farmacéutica es obtenida por granulación húmeda, utilizando Metformina molida a polvo fino y baja carga de excipientes, consistentes en un aglutinante, en este caso Povidona y Estearato de Magnesio como lubricante durante la compresión. El hecho de utilizar la Metformina molida, mejora notablemente la compresibilidad de la misma, permitiendo a su vez optimizar las condiciones operativas. La composición farmacéutica mejorada, comprendiendo la combinación de Teneligli
